ASENAPINE MALEATE (asenapine maleate) by AbbVie is disorder, is unknown. Approved for schizophrenia. First approved in 2020.
Drug data last refreshed 21h ago
disorder, is unknown. It has been suggested that the efficacy of asenapine in schizophrenia could be mediated through a combination of antagonist activity at D 2 and 5-HT 2A receptors.
Worked on ASENAPINE MALEATE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.